Immunotherapy drug aims to keep adrenocortical cancer at bay

NCT ID NCT07085572

Recruiting now Disease control Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether the immunotherapy drug cemiplimab can delay or prevent cancer progression in people with advanced adrenocortical cancer whose disease has been stabilized by initial chemotherapy. About 31 participants will receive cemiplimab every three weeks. The main goal is to see how many remain progression-free after six months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cemiplimab (a cancer immunotherapy drug)
What this could lead to: If it works, this could offer a new maintenance option to delay cancer progression in patients with advanced adrenocortical cancer.
What could go wrong: This is a small, early-phase trial with only 31 participants, so results may not apply broadly. The drug may not effectively prevent progression and could cause immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADRENAL CORTICAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adrenal carcinoma adrenal cortex carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADRENAL CORTICAL CARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

S.C. Oncologia - ASST Spedali Civili di Brescia
RECRUITING

Brescia, Brescia, 25123, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.